Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cesare Gridelli

Showing results (191-200 of 357) with videos related to

Pageof 36
Sort By:
Translational Lung Cancer Research|December 13, 2023
A retrospective comparative cohort study: concurrent versus consolidative immunotherapy with chemoradiotherapy in EGFR- or ALK-negative unresectable stage III non-small cell lung cancerYonghui Wu, Zhiyi Guo, Lu Meng, et al.
Expert Opinion on Pharmacotherapy|February 16, 2016
Optimal drugs for second-line treatment of patients with small-cell lung cancerAntonio Rossi, Paola Claudia Sacco, Assunta Sgambato, et al.
Expert Opinion on Emerging Drugs|September 26, 2014
Emerging drugs targeting PD-1 and PD-L1: reality or hope?Francesca Casaluce, Assunta Sgambato, Paola Claudia Sacco, et al.
Current Drug Safety|September 29, 2015
Anti PD-1 and PDL-1 Immunotherapy in the Treatment of Advanced Non- Small Cell Lung Cancer (NSCLC): A Review on Toxicity Profile and its ManagementAssunta Sgambato, Francesca Casaluce, Paola C Sacco, et al.
Translational Lung Cancer Research|July 18, 2017
Predictive biomarkers of immunotherapy for non-small cell lung cancer: results from an Experts Panel Meeting of the Italian Association of Thoracic OncologyCesare Gridelli, Andrea Ardizzoni, Massimo Barberis, et al.
The Oncologist|June 22, 2005
Treatment of small cell lung cancer in the elderlyAntonio Rossi, Paolo Maione, Giuseppe Colantuoni, et al.
Current Pharmaceutical Design|October 22, 2013
Irreversible EGFR inhibitors in the treatment of advanced NSCLCPaolo Maione, Antonio Rossi, Marianna Bareschino, et al.
Expert Opinion on Pharmacotherapy|January 10, 2017
Developments in pharmacotherapy for treating metastatic non-small cell lung cancerAntonio Rossi, Paola Claudia Sacco, Giuseppe Santabarbara, et al.
Current Clinical Pharmacology|May 4, 2016
Resistance to Crizotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) with ALK Rearrangement: Mechanisms, Treatment Strategies and New Targeted TherapiesFrancesca Casaluce, Assunta Sgambato, Paola Claudia Sacco, et al.
Expert Review of Anticancer Therapy|October 17, 2015
Current challenges of lung cancer care in an aging populationPaola Claudia Sacco, Francesca Casaluce, Assunta Sgambato, et al.
Pageof 36

Showing results (191-200 of 357) with videos related to

Sort By:
Pageof 36
Translational Lung Cancer Research|December 13, 2023
A retrospective comparative cohort study: concurrent versus consolidative immunotherapy with chemoradiotherapy in EGFR- or ALK-negative unresectable stage III non-small cell lung cancerYonghui Wu, Zhiyi Guo, Lu Meng, et al.
Expert Opinion on Pharmacotherapy|February 16, 2016
Optimal drugs for second-line treatment of patients with small-cell lung cancerAntonio Rossi, Paola Claudia Sacco, Assunta Sgambato, et al.
Expert Opinion on Emerging Drugs|September 26, 2014
Emerging drugs targeting PD-1 and PD-L1: reality or hope?Francesca Casaluce, Assunta Sgambato, Paola Claudia Sacco, et al.
Current Drug Safety|September 29, 2015
Anti PD-1 and PDL-1 Immunotherapy in the Treatment of Advanced Non- Small Cell Lung Cancer (NSCLC): A Review on Toxicity Profile and its ManagementAssunta Sgambato, Francesca Casaluce, Paola C Sacco, et al.
Translational Lung Cancer Research|July 18, 2017
Predictive biomarkers of immunotherapy for non-small cell lung cancer: results from an Experts Panel Meeting of the Italian Association of Thoracic OncologyCesare Gridelli, Andrea Ardizzoni, Massimo Barberis, et al.
The Oncologist|June 22, 2005
Treatment of small cell lung cancer in the elderlyAntonio Rossi, Paolo Maione, Giuseppe Colantuoni, et al.
Current Pharmaceutical Design|October 22, 2013
Irreversible EGFR inhibitors in the treatment of advanced NSCLCPaolo Maione, Antonio Rossi, Marianna Bareschino, et al.
Expert Opinion on Pharmacotherapy|January 10, 2017
Developments in pharmacotherapy for treating metastatic non-small cell lung cancerAntonio Rossi, Paola Claudia Sacco, Giuseppe Santabarbara, et al.
Current Clinical Pharmacology|May 4, 2016
Resistance to Crizotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) with ALK Rearrangement: Mechanisms, Treatment Strategies and New Targeted TherapiesFrancesca Casaluce, Assunta Sgambato, Paola Claudia Sacco, et al.
Expert Review of Anticancer Therapy|October 17, 2015
Current challenges of lung cancer care in an aging populationPaola Claudia Sacco, Francesca Casaluce, Assunta Sgambato, et al.
Pageof 36